Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05684796

Comparison of Two Pulmonary Embolism Treatments

Conditions: Pulmonary Embolism Acute

Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: NA
Enrollment: 100
Sponsor: Penumbra Inc.

Location: The University of Arizona - Banner Tucson Arizona

Summary

The primary objective of this trial is to evaluate the safety and efficacy of treatment with anticoagulation alone versus anticoagulation and mechanical aspiration thrombectomy with the Indigo Aspiration System for the treatment of intermediate-high risk acute pulmonary embolism (PE).

Eligibility Criteria

Inclusion Criteria: 1. Age 18-80 years old 2. Clinical signs and symptoms consistent with acute PE with duration of 14 days or less 3. Objectively confirmed acute PE, based on computed tomographic pulmonary angiography (CTPA) imaging showing a filling defect in at least one main or proximal lobar pulmonary artery 4. Classification of intermediate high-risk PE as demonstrated by right ventricular dysfunction with RV/LV ratio ≥1.0 on CTPA and elevated cardiac biomarkers, including cardiac troponin, BNP, and/or NT-pro BNP above the upper limit of normal 5. Jugular or femoral access deemed suitable to accommodate pulmonary artery intervention with the Indigo Aspiration System 6. Informed consent is obtained from either the patient or legally authorized representative (LAR) Exclusion Criteria: 1. Administration of thrombolytic agents or glycoprotein IIb/IIIa receptor antagonist within 30 days prior to baseline imaging 2. Hemodynamic instability with any of the following present: 1. Cardiac arrest 2. Obstructive shock or persistent hypotension defined as systolic blood pressure (BP) \15 min, or requiring vasopressor or inotropic support to achieve a systolic BP ≥90 mmHg 3. Patients on ECMO 4. National Early Warning Score (NEWS) 2 ≥9 5. History, imaging or hemodynamic findings consistent with chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis 6. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, that catheter-based intervention is not appropriate for the patient 7. Allergy, hypersensitivity, or heparin induced thrombocytopenia (HIT) 8. Contraindication or sensitivity to iodinated intravascular contrast that cannot be adequately premedicated 9. \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05684796). StuddyBuddy aggregates publicly available trial information.